Previous 10 | Next 10 |
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction an...
2023-08-09 23:41:24 ET Dyadic International, Inc. (DYAI) Q2 2023 Earnings Conference Call August 09, 2023 05:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business...
2023-08-09 16:38:25 ET Dyadic International press release ( NASDAQ: DYAI ): Q2 GAAP EPS of -$0.07 misses by $0.02 . Revenue of $837.15M (+27.1% Y/Y). For further details see: Dyadic International GAAP EPS of -$0.07 misses by $0.02, revenue of $837.15M
Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited (EDCL) in Bangladesh Progress in developing animal-free recombinant s...
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to de...
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to ad...
Dosing of patients completed at the end of February Data Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levels No Serious Adverse Events (SAE’s) or Adverse Events of Special Interest re...
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative mic...
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
2023-05-15 15:05:44 ET Summary Today, we take our first look at Maravai LifeSciences Holdings, Inc which was the subject of new takeover rumors last week. Both business segments of this nucleic acid production and biologics safety testing have seen sales fall drastically thanks to...
News, Short Squeeze, Breakout and More Instantly...
Dyadic International Inc. Company Name:
DYAI Stock Symbol:
OTCMKTS Market:
Dyadic International Inc. Website:
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for ...
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well a...
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against C...